Precision Biosciences (DTIL) EBT (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly EBT of -$8.6 million for Q1 2026, up 59.69% year-over-year from -$5.4 million in Q1 2025, and down 165.96% quarter-over-quarter from $13.0 million in Q4 2025.
Precision Biosciences (DTIL) EBT (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported EBT for 9 consecutive years, with -$8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 59.69% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$45.4 million (up 23.13% YoY), while the FY2025 annual figure was -$193.2 million, down 23.62% from the prior year.
- EBT retreated to -$8.6 million in Q1 2026 per DTIL's latest filing, from $13.0 million in the prior quarter.
- Across five years, EBT topped out at $15.6 million in Q2 2024 and bottomed at -$35.9 million in Q2 2022.
- Historically, EBT has averaged -$14.5 million across 5 years, with a median of -$13.4 million in 2023.
- Annual changes were most pronounced in 2024 — EBT jumped 305.3% — and 2025, when it slumped 586.67%.
- Precision Biosciences' EBT stood at -$10.9 million in 2022, then slipped by 23.73% to -$13.4 million in 2023, then tumbled by 77.66% to -$23.9 million in 2024, then jumped by 154.45% to $13.0 million in 2025, then tumbled by 165.96% to -$8.6 million in 2026.
- Business Quant data shows DTIL's EBT at -$8.6 million in Q1 2026, $13.0 million in Q4 2025, and -$27.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 81.49 Mn |
| 10 | Precision Biosciences | 226.63 Mn | 139.08 Mn | - | -18.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.73 Mn |
| Mar 31, 2026 | -8.58 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Sep 30, 2025 | -27.65 Mn |
| Jun 30, 2025 | -22.17 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -23.87 Mn |
| Sep 30, 2024 | -29.46 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -13.44 Mn |
| Sep 30, 2023 | -11.18 Mn |
| Jun 30, 2023 | -7.58 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -10.86 Mn |
| Sep 30, 2022 | -14.03 Mn |
| Jun 30, 2022 | -35.86 Mn |
| Mar 31, 2022 | -34.23 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -22.12 Mn |